Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout
- PMID: 17223663
- PMCID: PMC1954685
- DOI: 10.1136/ard.2006.060368
Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout
Abstract
Objectives: To determine whether hypouricaemic treatment results in the disappearance of urate crystals from gouty joints and to define the time required.
Methods: In 18 patients with monosodium urate (MSU) crystal proven gout, and after the initiation of successful serum uric acid (SUA)-lowering treatment, an arthrocentesis of the asymptomatic signal joint (11 knees, 7 first metatarsophalangeal joints) was performed every 3 months to obtain a synovial fluid (SF) sample. The sample was then analysed for the presence of MSU crystals, and the number of crystals/400x field was noted. SUA levels and the duration of gout were also noted.
Results: MSU crystals disappeared from the SF of all 18 joints after reduction of SUA to normal levels. The time required for disappearance ranged from 3 to 33 months; disappearance time correlated with the duration of gout (r(s) = 0.71; p<0.01). The median number of MSU crystals in the SF samples before urate-lowering treatment was 7.5 (2.5-11) crystals/400x field, reducing to 3 (1-6.5) crystals/400x field (p<0.05) at 3 months. Crystal counts continued to decrease after 3 months.
Conclusions: In gout, reduction of SUA to normal levels results in disappearance of urate crystals from SF, requiring a longer time in those patients with gout of longer duration. This indicates that urate crystal deposition in joints is reversible. Normalisation of SUA levels results in a decrease in the concentration of MSU crystals in SF in the asymptomatic gouty joints. This may partially explain the reduced frequency of gouty attacks when a patient has been treated with SUA-lowering drugs.
Conflict of interest statement
Conflict of interest: None declared.
Similar articles
-
Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?J Rheumatol. 2001 Mar;28(3):577-80. J Rheumatol. 2001. PMID: 11296962 Clinical Trial.
-
Temporal evolution of urate crystal deposition over articular cartilage after successful urate-lowering therapy in patients with gout: An ultrasonographic perspective.Mod Rheumatol. 2017 May;27(3):518-523. doi: 10.1080/14397595.2016.1214229. Epub 2016 Aug 5. Mod Rheumatol. 2017. PMID: 27492663
-
Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout.Arthritis Rheum. 1986 Dec;29(12):1480-4. doi: 10.1002/art.1780291209. Arthritis Rheum. 1986. PMID: 3801071
-
Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL?Postgrad Med. 2016 Sep;128(7):706-15. doi: 10.1080/00325481.2016.1221732. Epub 2016 Aug 25. Postgrad Med. 2016. PMID: 27558643 Review.
-
Diagnosis of gout.Minerva Med. 2007 Dec;98(6):759-67. Minerva Med. 2007. PMID: 18299687 Review.
Cited by
-
Goals of gout treatment: a patient perspective.Clin Rheumatol. 2018 Sep;37(9):2557-2566. doi: 10.1007/s10067-018-4243-7. Epub 2018 Aug 4. Clin Rheumatol. 2018. PMID: 30078087
-
Managing Gout in the Patient with Renal Impairment.Drugs Aging. 2018 Apr;35(4):263-273. doi: 10.1007/s40266-018-0517-7. Drugs Aging. 2018. PMID: 29435850 Review.
-
The first metatarsophalangeal joint in gout: a systematic review and meta-analysis.BMC Musculoskelet Disord. 2016 Feb 11;17:69. doi: 10.1186/s12891-016-0919-9. BMC Musculoskelet Disord. 2016. PMID: 26864742 Free PMC article.
-
The detection of calcium pyrophosphate crystals in sequential synovial fluid examinations of patients with osteoarthritis: once positive, always positive.Clin Rheumatol. 2013 May;32(5):671-2. doi: 10.1007/s10067-012-2147-5. Epub 2012 Dec 28. Clin Rheumatol. 2013. PMID: 23271610
-
Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved.Rheumatol Int. 2010 Feb;30(4):495-503. doi: 10.1007/s00296-009-1002-8. Epub 2009 Jun 20. Rheumatol Int. 2010. PMID: 19543895
References
-
- Yü T ‐ F, Gutman A B. Principles of current management of primary gout. Am J Med Sci 1967254893–907. - PubMed
-
- Yü T ‐ F, Gutman A B. Mobilization of gouty tophi by protracted use of uricosuric agents. Am J Med 195111765–769. - PubMed
-
- Perez‐Ruiz F, Calabozo M, Pijoan J I, Herrero‐Beites A M, Ruibal A. Effect of urate‐lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 200247356–360. - PubMed
-
- Pascual E. Persistence of monosodium urate crystals, and low grade inflammation, in the synovial fluid of untreated gout. Arthritis Rheum 199134141–145. - PubMed
-
- Pascual E, Batlle‐Gualda E, Martínez A, Rosas J, Vela P. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med 1999131756–759. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical